Letter by Choi et al Regarding Article, “Effects of the Selective Estrogen Receptor Modulator Raloxifene on Coronary Outcomes in the Raloxifene Use for the Heart Trial: Results of Subgroup Analyses by Age and Other Factors”

Abstract

To the Editor: We read with great interest the subgroup analyses of the Raloxifene use for the Heart (RUTH) trial.1 Although this post hoc analysis did not show benefit of raloxifene for any prespecified group, we believe that one particular subgroup, not defined in this study, may benefit from raloxifene in the reduction of coronary outcomes. Although RUTH did not show an overall benefit in postmenopausal women with established …